Brandon Luber
Overview
Explore the profile of Brandon Luber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
4699
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thiruvengadam S, Tieu A, Luber B, Wang H, Meltzer S
Sci Rep
. 2020 Mar;
10(1):4899.
PMID: 32184470
Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC). Methods of identifying BE patients at high risk for progression to high-grade dysplasia (HGD) or EAC are needed...
2.
Llosa N, Luber B, Siegel N, Awan A, Oke T, Zhu Q, et al.
Cancer Immunol Res
. 2019 Aug;
7(10):1574-1579.
PMID: 31439614
Mismatch-repair deficiency in solid tumors predicts their response to PD-1 blockade. Based on this principle, pembrolizumab is approved as standard of care for patients with unresectable or metastatic microsatellite instability-high...
3.
Llosa N, Luber B, Tam A, Smith K, Siegel N, Awan A, et al.
Clin Cancer Res
. 2019 May;
25(17):5250-5259.
PMID: 31061070
Purpose: Approximately 10% of patients with mismatch repair-proficient (MMRp) colorectal cancer showed clinical benefit to anti-PD-1 monotherapy (NCT01876511). We sought to identify biomarkers that delineate patients with immunoreactive colorectal cancer...
4.
Rowe S, Luber B, Makell M, Brothers P, Santmyer J, Schollenberger M, et al.
Mol Oncol
. 2018 Aug;
12(10):1661-1672.
PMID: 30113761
Melanoma currently lacks a reliable blood-based biomarker of disease activity, although circulating tumor DNA (ctDNA) may fill this role. We investigated the clinical utility (i.e., impact on clinical outcomes and...
5.
Boudadi K, Suzman D, Anagnostou V, Fu W, Luber B, Wang H, et al.
Oncotarget
. 2018 Jul;
9(47):28561-28571.
PMID: 29983880
AR-V7-expressing metastatic prostate cancer is an aggressive phenotype with poor progression-free survival (PFS) and overall survival (OS). Preliminary evidence suggests that AR-V7-positive tumors may be enriched for DNA-repair defects, perhaps...
6.
Antonarakis E, Lu C, Luber B, Liang C, Wang H, Chen Y, et al.
Eur Urol
. 2018 Feb;
74(2):218-225.
PMID: 29439820
Background: Inherited DNA-repair gene mutations are more prevalent in men with advanced prostate cancer than previously thought, but their clinical implications are not fully understood. Objective: To investigate the clinical...
7.
Teply B, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, et al.
Lancet Oncol
. 2017 Dec;
19(1):76-86.
PMID: 29248236
Background: Prostate cancer that progresses after enzalutamide treatment is poorly responsive to further antiandrogen therapy, and paradoxically, rapid cycling between high and low serum testosterone concentrations (bipolar androgen therapy [BAT])...
8.
Llosa N, Cooke K, Chen A, Gamper C, Klein O, Zambidis E, et al.
Biol Blood Marrow Transplant
. 2017 Aug;
23(12):2127-2136.
PMID: 28807769
High-risk, recurrent, or refractory solid tumors in pediatric, adolescent, and young adult (AYA) patients have an extremely poor prognosis despite current intensive treatment regimens. We piloted an allogeneic bone marrow...
9.
Luo J, Luber B, Wang H, Antonarakis E
Eur Urol
. 2017 Jul;
72(6):e170-e171.
PMID: 28693939
No abstract available.
10.
Antonarakis E, Lu C, Luber B, Wang H, Chen Y, Zhu Y, et al.
J Clin Oncol
. 2017 Apr;
35(19):2149-2156.
PMID: 28384066
Purpose We reported previously that the detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells (CTCs) correlated with poor outcomes from the use of abiraterone and enzalutamide...